The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Richard Saynor, CEO of Sandoz, expects biosimilars referencing semaglutide to be available in Canada in early 2026. This projection comes as Novo Nordisk's patent protection for the drug nears its end. Sandoz intends to capitalize on the commercial opportunity as soon as regulatory approval is granted.
Hair loss, or 'GLP-1 shedding,' can be a concerning side effect for those using GLP-1 drugs. However, solutions are available to effectively address this issue. A dermatologist provides insights into managing hair loss associated with these medications.
Meghan Trainor's slimmer appearance, attributed to Mounjaro, has ignited online discussions. While some celebrate her health dedication, others miss her earlier look. The debate highlights body image and societal pressures.
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
Research indicates that a berry utilized in traditional Chinese medicine can effectively restore healthy fat metabolism and enhance insulin sensitivity within a mouse model of diabetes. This finding suggests potential benefits for managing metabolic disorders.
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
The global peptide CDMO 2.0 market is poised for substantial growth, driven by increasing demand for peptide therapeutics and advancements in manufacturing technologies. This growth is fueled by the need for flexible, scalable, and efficient peptide production to meet the demands of both established pharmaceutical companies and emerging biotechs.
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
Actress Tamannaah Bhatia has responded to speculation surrounding her recent physical transformation, specifically addressing rumors about Ozempic use. In a recent interview, Bhatia clarified her stance, emphasizing her commitment to body positivity and dismissing any connection to the drug.
